CytomX Therapeutics announced positive interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in patients with advanced, late-line colorectal cancer (CRC), based on an April 7, 2025 data cutoff. The study showed a 28% confirmed overall response rate (ORR) in 18 efficacy-evaluable patients across prioritized expansion doses (7.2, 8.6, and 10 mg/kg Q3W). Notably, at the highest dose of 10 mg/kg Q3W, the confirmed ORR was 43% (3/7).
The CX-2051 study also demonstrated a 94% disease control rate (DCR) and a preliminary median progression-free survival (PFS) of 5.8 months, with 10 of 18 patients remaining on study treatment. The safety profile was generally well-tolerated, with manageable adverse events and no dose-limiting toxicities reported. These results validate EpCAM as an oncology target and support plans to initiate a Phase 2 study in CRC in the first half of 2026.
Concurrently, CytomX reported strong first quarter 2025 financial results, with total revenue increasing to $50.9 million from $41.5 million in Q1 2024. This increase was driven by higher revenue recognition from the Bristol Myers Squibb collaboration and accelerated revenue from the Amgen collaboration due to the decision not to further develop the CX-904 program. The company reported a net income of $23.5 million for the quarter, compared to $13.8 million in Q1 2024, with basic and diluted earnings per share of $0.27.
Total operating expenses decreased to $28.3 million from $29.8 million in Q1 2024, despite including $2.9 million in restructuring expenses. Research and development expenses decreased by $3.2 million to $18.9 million, primarily due to reduced preclinical and manufacturing activities, partially offset by increased clinical trial activities for CX-2051 and CX-801. As of March 31, 2025, cash, cash equivalents, and investments totaled $79.9 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.